Our data showing that leishmanization with parasites plus Pam3CSK4 protects bothC57BL/6 and BALB/c mice against lesions are very promising, and point towards thefeasibility of the use of TLR2 agonists as immune adjuvants against leishmaniasis.However, our studies have also revealed that the mechanism underlying protection isvery different between the two mouse strains. Here, TLR2 is linked to leishmaniasis.